



Bilag 10

Referenceliste MTV influenzavaccination (09.10.2020)

- (1) Bekendtgørelse om gratis influenzavaccination til visse persongrupper
BEK nr 988 af 25/09/2019. Opdateret: 25.september 2019. Senest hentet: 010920. Link: <https://www.retsinformation.dk/eli/lta/2019/988>.
- (2) Anonymous . Recommended composition of influenza virus vaccines for use in the 2018-2019 northern hemisphere influenza season. Opdateret: 22 February 2018. Senest hentet: 010920. Link: https://www.who.int/influenza/vaccines/virus/recommendations/2018_19_north/en/.
- (3) Anonymous . SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET
Fluad, suspension for injection in pre-filled syringe Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59C.1 (2014/2015 SEASON). . Senest hentet: 29.sep.2020. Link: https://mri.cts-mrp.eu/Human/Downloads/IT_H_0104_001_FinalPI.pdf.
- (4) Anonymous . Nationalbanken - Valutakurser. . Senest hentet: 8.okt.2020. Link: <https://www.nationalbanken.dk/valutakurser>.
- (5) Ahmed F, Lindley MC, Allred N, Weinbaum CM, Grohskopf L. Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: systematic review and grading of evidence. *Clinical Infectious Diseases* 2014;58(1):50-57.
- (6) Ambrose C.S., Wu X., Knuf M., Wutzler P. Corrigendum to "The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies" [*Vaccine* 30 (2012) 886-892] DOI: 10.1016/j.vaccine.2011.11.104. *Vaccine* 2015;33(39):5235.
- (7) Ambrose CS. 2015–16 US Influenza Vaccine Effectiveness Influenza Clinical Investigation for Children (ICICLE) Study. In: Advisory Committee on Immunization Practices; June 22–23, **2016**; Atlanta, GA. 2016.
- (8) Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. *Vaccine* 2012;30(5):886-892.
- (9) Andersohn F, Bornemann R, Damm O, Frank M, Mittendorf T, Theidel U. Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment. *GMS Health Technology Assessment* 2014;10:o03.
- (10) Antonova EN, Rycroft CE, Ambrose CS, Heikkinen T, Principi N. Burden of paediatric influenza in Western Europe: a systematic review. *BMC Public Health* 2012;12:968-2458-12-968.
- (11) Australian Government Department of Health. . The Australian Immunisation Handbook. Opdateret: 12. april 2019. Link: <https://immunisationhandbook.health.gov.au/about-the-handbook>.



- (12) Baay M., Bollaerts K., Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults. *Vaccine* 2018;36(29):4207-4214.
- (13) Baguelin M, Camacho A, Flasche S, Edmunds WJ. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study. *BMC Med* 2015;13:236-015-0452-y.
- (14) Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. *PLoS Med* 2013;10(10):e1001527.
- (15) BaNguz A., Shah A., Bresee J.S., Lafond K.E., Cavallaro K., Shefer A., et al. Supporting national immunization technical advisory groups (NITAGs) in resource-constrained settings. New strategies and lessons learned from the Task Force for Global Health's Partnership for influenza vaccine introduction. *Vaccine* 2019(pagination):ate of Pubaton: 2019.
- (16) Bart S., Cannon K., Herrington D., Mills R., ForleoNeto E., Lindert K., et al. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study. *Human Vaccines and Immunotherapeutics* 2016;12(9):2278-2288.
- (17) Baum U, Kulathinal S, Auranen K, Nohynek H. Effectiveness of two influenza vaccines in nationwide cohorts of Finnish two-year-old children in the seasons 2015/16-2017/18. *Clin Infect Dis* 2020.
- (18) Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. *J Pediatr* 2000;136(2):168-175.
- (19) Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. *N Engl J Med* 1998;338(20):1405-1412.
- (20) Belshe RB, Swierkosz EM, Anderson EL, Newman FK, Nugent SL, Maassab HF. Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine. *J Infect Dis* 1992;165(4):727-732.
- (21) Benedict K.M., Santibanez T.A., Kahn K.E., Pabst L.J., Bridges C.B., Kennedy ED. Receipt and effectiveness of influenza vaccination reminders for adults, 2011-2012 season, United States. *Influenza and other Respiratory Viruses* 2018;12(5):605-612.
- (22) Benet T, Regis C, Voirin N, Robert O, Lina B, Cronenberger S, et al. Influenza vaccination of healthcare workers in acute-care hospitals: a case-control study of its effect on hospital-acquired influenza among patients. *BMC Infect Dis* 2012;12:30-2334-12-30.
- (23) Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. *Pediatr Infect Dis J* 2004;23(2):138-144.
- (24) Bertram MY, Lauer JA, De Joncheere K, Edejer Tea. Cost-effectiveness thresholds: pros and consArticle has an altmetric score of 58 . *Bulletin of the World Health Organization* 2016;94(30.april 2020):925-930.



- (25) Bilcke J, Coenen S, Beutels P. Influenza-like-illness and clinically diagnosed flu: disease burden, costs and quality of life for patients seeking ambulatory care or no professional care at all. *PLoS One* 2014;9(7):e102634.
- (26) Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naïve children. *Pediatr Infect Dis J* 2009;28(5):365-371.
- (27) Brooks WA, Zaman K, Lewis KD, Ortiz JR, Goswami D, Feser J, et al. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. *Lancet Glob Health* 2016;4(12):e946-e954.
- (28) Buchan SA, Booth S, Scott AN, Simmonds KA, Svenson LW, Drews SJ, et al. Effectiveness of Live Attenuated vs Inactivated Influenza Vaccines in Children During the 2012-2013 Through 2015-2016 Influenza Seasons in Alberta, Canada: A Canadian Immunization Research Network (CIRN) Study. *JAMA Pediatr* 2018;172(9):e181514.
- (29) Carman WF, Elder AG, Wallace LA, McAulay K, Walker A, Murray GD, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. *Lancet* 2000;355(9198):93-97.
- (30) Caspard H, Gaglani M, Clipper L, et al. Multicenter study of live-attenuated influenza vaccine effectiveness in children, 2014–15. *Open Forum Infect Dis* 2015;2(1352).
- (31) Caspard H, Gaglani M, Clipper L, Belongia EA, McLean HQ, Griffin MR, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States. *Vaccine* 2016;34(1):77-82.
- (32) Caspard H, Mallory RM, Yu J, Ambrose CS. Live-Attenuated Influenza Vaccine Effectiveness in Children From 2009 to 2015-2016: A Systematic Review and Meta-Analysis. *Open Forum Infectious Diseases* 2017;4(3):of111.
- (33) Cate TR, Rayford Y, Nino D, Winokur P, Brady R, Belshe R, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. *Vaccine* 2010;28(9):2076-2079.
- (34) Chae W., Kim P., Hwang B.J., Seong BL. Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay. *Vaccine* 2019;37(11):1457-1466.
- (35) Chan AL, Shie HJ, Lee YJ, Lin SJ. The evaluation of free influenza vaccination in health care workers in a medical center in Taiwan. *Pharm World Sci* 2008;30(1):39-43.
- (36) Chan SS. Does vaccinating ED health care workers against influenza reduce sickness absenteeism? *Am J Emerg Med* 2007;25(7):808-811.
- (37) Choi W.S., Noh J.Y., Song J.Y., Cheong H.J., Wie S.H., Lee J.S., et al. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects. *Human Vaccines and Immunotherapeutics* 2017;13(7):1653-1660.
- (38) Christiansen CF, Thomsen RW, Schmidt M, Pedersen L, Sørensen HT. Influenza vaccination and 1-year risk of myocardial infarction, stroke, heart failure, pneumonia, and mortality among intensive care unit survivors aged 65 years or older: a nationwide population-based cohort study. *Intensive Care Med* 2019;45(7):957-967.



- (39) Clover RD, Crawford S, Glezen WP, Taber LH, Matson CC, Couch RB. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. *J Infect Dis* 1991;163(2):300-304.
- (40) Cochran LW, Black S, Klein NP, Dekker CL, Lewis E, Reingold AL. Vaccine effectiveness against laboratory-confirmed influenza in infants: A matched case control study. *Hum Vaccin* 2010;6(9):10.4161/hv.6.9.12470. Epub 2010 Sep 23.
- (41) Colombo C, Argiolas L, La Vecchia C, Negri E, Meloni G, Meloni T. Influenza vaccine in healthy preschool children. *Rev Epidemiol Sante Publique* 2001;49(2):157-162.
- (42) Colombo GL, Ferro A, Vinci M, Zordan M, Serra G. Cost-benefit analysis of influenza vaccination in a public healthcare unit. *Ther Clin Risk Manag* 2006;2(2):219-226.
- (43) Committee on Infectious Diseases, American Academy of Pediatrics. Recommended Childhood and Adolescent Immunization Schedules: United States, 2019: *Pediatrics* 2019;143(3):1-3.
- (44) Committee on Infectious Diseases, American Academy of Pediatrics. Influenza vaccine recommendations for children and youth for the 2008-2009 season. *Paediatr child health* 2008;13(8):688-91.
- (45) Cost AA, Hiser MJ, Hu Z, Cooper MJ, Hawksworth AW, Radin JM, et al. Brief report: mid-season influenza vaccine effectiveness estimates for the 2013-2014 influenza season. *MSMR* 2014;21(6):15-17.
- (46) Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. *Vaccine* 2007;25(44):7656-7663.
- (47) Dabestani NM, Leidner AJ, Seiber EE, Kim H, Graitcer SB, Foppa IM, et al. A review of the cost-effectiveness of adult influenza vaccination and other preventive services. *Prev Med* 2019;126:105734.
- (48) D'Angiolella LS, Lafranconi A, Cortesi PA, Rota S, Cesana G, Mantovani LG. Costs and effectiveness of influenza vaccination: a systematic review. *Ann Ist Super Sanita* 2018;54(1):49-57.
- (49) Dansk Lægemiddel Information A/S. . Indlægssedler. . Senest hentet: 8.okt.2020. Link: <https://www.indlaegssedler.dk/>.
- (50) Dansk Selskab for Infektionsmedicin. Retningslinjer for håndtering af influenza 2018.
- (51) De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. *Vaccine* 1999;17(23-24):3094-3101.
- (52) Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 ((R)) adjuvant: results from a dose-finding clinical trial in older adults. *Hum Vaccin Immunother* 2012;8(2):216-227.
- (53) Desheva I, Danini GV, Grigor'eva EP, Donina SA, Kiseleva IV, Rekstin AR, et al. The investigation of the safety, genetic stability and immunogenicity of live influenza vaccine for adults in vaccination of 3-6 years old children. *Vopr Virusol* 2002;47(4):21-24.



- (54) DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. *Vaccine* 2013;31(6):861-866.
- (55) DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. *N Engl J Med* 2014;371(7):635-645.
- (56) DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines. *Vaccine* 2015;33(38):4988-4993.
- (57) DiezDomingo J., de Martino M., Lopez J.G.S., Zuccotti G.V., Icardi G., Villani A., et al. Safety and tolerability of cell culture-derived and egg-derived trivalent influenza vaccines in 3 to <18-year-old children and adolescents at risk of influenza-related complications. *International Journal of Infectious Diseases* 2016;49:171-178.
- (58) Domnich A, Arata L, Amicizia D, Puig-Barbera J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. *Vaccine* 2017;35(4):513-520.
- (59) Drummond ME, Sculpher MJ, Torrance GW, et al. *Methods for the economic evaluation of health care programmes*. 3rd ed. Oxford University Press, 2005.
- (60) ECDC, European Centre for Disease Prevention and Control, An agency of the European Union. Seasonal influenza vaccination and antiviral use in EU/EEA Member States. TECHNICAL REPORT. Overview of vaccine recommendations for 2017–2018 and vaccination coverage rates for 2015–2016 and 2016–2017 influenza seasons
European Centre for Disease Prevention and Control, ecdc.europa, november 2018. 47 s.
- (61) ECDC, European Centre for Disease Prevention and Control, An agency of the European Union. Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over ECDC TECHNICAL REPORT European Centre for Disease Prevention and Control, Stockholm, 2020. 144 (Catalogue number TQ-02-20-772-EN-N).
- (62) ECDC, European Centre for Disease Prevention and Control, An agency of the European Union. . Factsheet about seasonal influenza (ECDC factsheet). Opdateret: [2015]. Senest hentet: 5/2-2020. Link: <https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet>.
- (63) Elliott S.T.C., Keaton A.A., Chu J.D., Reed C.C., Garman B., Patel A., et al. A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses. *Hum Gene Ther* 2018;29(9):1044-1055.
- (64) European Medicines Agency EMA. . ANNEX, I SUMMARY OF PRODUCT CHARACTERISTICS Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal). . Senest hentet: 29.sep.2020. Link: https://www.ema.europa.eu/en/documents/product-information/fluenz-tetra-epar-product-information_en.pdf.
- (65) European Medicines Agency EMA. . . Senest hentet: 6.okt.2020. Link: <https://www.ema.europa.eu/en>.
- (66) Esposito S., Bonanni P., Maggi S., Tan L., Ansaldi F., Lopalco P.L., et al. Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious



Diseases and Immunological Disorders (WAidid). Human Vaccines and Immunotherapeutics 2016;12(7):1777-1794.

(67) EUnetHTA, European Network for Health Technology Assessment. . Joint Action on HTA 2012-2015 HTA Core Model Version 3.0 (The HTA Core Model® is a *methodological framework* for production and sharing of HTA information.). Opdateret: 25 jan 2016. Senest hentet: 010920.2019. Link: <https://eunetha.eu/wp-content/uploads/2018/03/HTACoreModel3.0-1.pdf>.

(68) EuroQol Research Foundation. . EQ-5d - instrument. . Senest hentet: 8.okt.2020. Link: <https://euroqol.org/eq-5d-instruments/>.

(69) Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200(2):172-180.

(70) Feng S, Cowling BJ, Kelly H, Sullivan SG. Estimating Influenza Vaccine Effectiveness With the Test-Negative Design Using Alternative Control Groups: A Systematic Review and Meta-Analysis. Am J Epidemiol 2018;187(2):389-397.

(71) Ferdinands JM, Gaglani M, Martin ET, Middleton D, Monto AS, Murthy K, et al. Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis 2019;220(8):1265-1275.

(72) Finnish Institute for Health and Welfare, THL. . Influenza vaccine. Opdateret: Updated: 14 Aug 2020. Senest hentet: 010920. Link: <https://thl.fi/en/web/infectious-diseases-and-vaccinations/vaccines-a-to-z/influenza-vaccine>.

(73) Flannery B, Reynolds SB, Blanton L, Santibanez TA, O'Halloran A, Lu PJ, et al. Influenza Vaccine Effectiveness Against Pediatric Deaths: 2010-2014. Pediatrics 2017;139(5):e20164244. doi: 10.1542/peds.2016-4244. Epub 2017 Apr 3.

(74) Norge Folkehelseinstituttet. . Influenzavaksine - veileder for helsepersonell. Opdateret: 2019. Senest hentet: 05/19.2020. Link: <https://www.fhi.no/nettpub/vaksinasjonsveilederen-for-helsepersonell/vaksiner-mot-de-enkelte-sykdommene/influenzavaksinasjon---veileder-for/>.

(75) Folkhälsomyndigheten S. Influenzavaccination till riskgrupper. Kunskapsunderlag Folkhälsomyndigheten, Sverige, 2016. 102 s.

(76) Fragaszy EB, Warren-Gash C, White PJ, Zambon M, Edmunds WJ, Nguyen-Van-Tam JS, et al. Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: Results from the Flu Watch cohort study. Influenza Other Respir Viruses 2018;12(1):171-182.

(77) Frey SE, Reyes MR, Reynales H, Bernal NN, Nicolay U, Narasimhan V, et al. Comparison of the safety and immunogenicity of an MF59(R)-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014;32(39):5027-5034.

(78) Gaglani M, Pruszyński J, Murthy K, Clipper L, Robertson A, Reis M, et al. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis 2016;213(10):1546-1556.



- (79) Gaillat J, Chidiac C, Fagnani F, Pecking M, Salom M, Veyssier P, et al. Morbidity and mortality associated with influenza exposure in long-term care facilities for dependent elderly people. *Eur J Clin Microbiol Infect Dis* 2009;28(9):1077-1086.
- (80) Gasparini R, Amicizia D, Lai PL, Rossi S, Panatto D. Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V (R) and Fluad (R)) in preventing hospitalization for influenza and pneumonia in the elderly: a matched case-control study. *Hum Vaccin Immunother* 2013;9(1):144-152.
- (81) Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. *Eur J Epidemiol* 2001;17(2):135-140.
- (82) Gesser-Edelsburg A, Mordini E, James JJ, Greco D, Green MS. Risk Communication Recommendations and Implementation During Emerging Infectious Diseases: A Case Study of the 2009 H1N1 Influenza Pandemic. *Disaster med public health prep* 2014:1-12.
- (83) Ghendon YZ, Kaira AN, Elshina GA. The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. *Epidemiol Infect* 2006;134(1):71-78.
- (84) Gravenstein S, Davidson HE, Han LF, Ogarek JA, Dahal R, Gozalo PL, et al. Feasibility of a cluster-randomized influenza vaccination trial in U.S. nursing homes: Lessons learned. *Hum Vaccin Immunother* 2018;14(3):736-743.
- (85) Gravenstein S, Davidson HE, Taljaard M, Ogarek J, Gozalo P, Han L, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. *Lancet Respir Med* 2017;5(9):738-746.
- (86) Grijalva CG, Craig AS, Dupont WD, Bridges CB, Schrag SJ, Iwane MK, et al. Estimating influenza hospitalizations among children. *Emerg Infect Dis* 2006;12(1):103-109.
- (87) Grohskopf L.A., Alyanak E., Broder K.R., Walter E.B., Fry A.M., Jernigan D.B. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season. *MMWR Recomm Rep* 2019;68(3):1-21.
- (88) Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season. *MMWR Recomm Rep* 2017;66(2):1-20.
- (89) Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. *MMWR Recomm Rep* 2018;67(3):1-20.
- (90) Grohskopf LA, Sokolow LZ, Fry AM, Walter EB, Jernigan DB. Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season. *MMWR Morb Mortal Wkly Rep* 2018;67(22):643-645.
- (91) Gruber WC, Taber LH, Glezen WP, Clover RD, Abell TD, Demmler RW, et al. Live attenuated and inactivated influenza vaccine in school-age children. *Am J Dis Child* 1990;144(5):595-600.



- (92) Guyatt G., Oxman A.D., Akl E.A., Kunz R., Vist G., Brozek J., et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64(4):383-394.
- (93) Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336(7650):924-926.
- (94) Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, Edmunds WJ, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. *Lancet Respir Med* 2014;2(6):445-454.
- (95) Hayward AC, Harling R, Wetten S, Johnson AM, Munro S, Smedley J, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. *BMJ* 2006;333(7581):1241.
- (96) Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children. *Am J Dis Child* 1991;145(4):445-448.
- (97) Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpää R, Vuorinen T, et al. Burden of influenza in children in the community. *J Infect Dis* 2004;190(8):1369-1373.
- (98) Heikkinen T, Tsolia M, Finn A. Vaccination of healthy children against seasonal influenza: a European perspective. *Pediatr Infect Dis J* 2013;32(8):881-888.
- (99) Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Ziegler T, Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. *Lancet Infect Dis* 2011;11(1):23-29.
- (100) Helmeke C. Effektivität der Influenza-Impfstoffe bei Kindern in Sachsen-Anhalt und Niedersachsen 2015/16. Dezernat Gesundheits- und Hygienemanagement Landesamt für Verbraucherschutz Sachsen-Anhalt. [2016]:1.
- (101) Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- (102) Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. *JAMA* 2003;290(12):1608-1616.
- (103) Hollmann M, Garin O, Galante M, Ferrer M, Dominguez A, Alonso J. Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients. *PLoS One* 2013;8(3):e60477.
- (104) Imai C, Toizumi M, Hall L, Lambert S, Halton K, Merollini K. A systematic review and meta-analysis of the direct epidemiological and economic effects of seasonal influenza vaccination on healthcare workers. *PLoS ONE [Electronic Resource]* 2018;13(6):e0198685.
- (105) Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. *Epidemiol Infect* 2005;133(4):687-693.
- (106) Ishikane M, Kamiya H, Kawabata K, Higashihara M, Sugihara M, Tabuchi A, et al. Seasonal influenza vaccine (A/New York/39/2012) effectiveness against influenza A virus of health care workers



in a long term care facility attached with the hospital, Japan, 2014/15: A cohort study. *J Infect Chemother* 2016;22(11):777-779.

(107) Ito Y, Sumi H, Kato T. Evaluation of influenza vaccination in health-care workers, using rapid antigen detection test. *J Infect Chemother* 2006;12(2):70-72.

(108) Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. *Lancet* 2018;391(10127):1285-1300.

(109) Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative Effectiveness of Cell-Cultured and Egg-Based Influenza Vaccines Among Elderly Persons in the United States, 2017-2018. *J Infect Dis* 2019;220(8):1255-1264.

(110) Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative effectiveness of influenza vaccines among the U.S. elderly, 2018-19. *J Infect Dis* 2020.

(111) Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative Effectiveness of Influenza Vaccines Among the United States Elderly, 2018-2019. *J Infect Dis* 2020;222(2):278-287.

(112) Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. *Lancet Infect Dis* 2015;15(3):293-300.

(113) Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. *N Engl J Med* 2000;342(4):232-239.

(114) Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among the U.S. elderly, 2017-18. *J Infect Dis* 2018.

(115) Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database Syst Rev* 2014;2014(4):CD008965.

(116) Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. *Cochrane Database of Systematic Reviews* 2018;2:004879.

(117) Jenkin DC, Mahgoub H, Morales KF, Lambach P, Nguyen-Van-Tam JS. A rapid evidence appraisal of influenza vaccination in health workers: An important policy in an area of imperfect evidence. *Vaccine: X* 2019;2:100036.

(118) Joint Committee on Vaccination and Immunisation. Advice on influenza vaccines for 2020/21 2019 (Influenza Advice·Updated Sep 24, 2019).

(119) Joshi AY, Iyer VN, St Sauver JL, Jacobson RM, Boyce TG. Effectiveness of inactivated influenza vaccine in children less than 5 years of age over multiple influenza seasons: a case-control study. *Vaccine* 2009;27(33):4457-4461.

(120) Keilman LJ. Seasonal Influenza (Flu). *Nurs Clin North Am* 2019;54(2):227-243.



(121) Keipp Talbot H., Dunning A.J., Robertson C.A., Landolfi V.A., Greenberg D.P., DiazGranados CA. Gastrointestinal events in high-dose vs standard-dose influenza vaccine recipients. Open Forum Infectious Diseases 2018;5(6) (pagination):ate of Pubaton: 2018.

(122) Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006;166(10):1121-1127.

(123) Khan AS, Polezhaev F, Vasiljeva R, Drinevsky V, Buffington J, Gary H, et al. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J Infect Dis 1996;173(2):453-456.

(124) Kheok SW, Chong CY, McCarthy G, Lim WY, Goh KT, Razak L, et al. The efficacy of influenza vaccination in healthcare workers in a tropical setting: a prospective investigator blinded observational study. Ann Acad Med Singapore 2008;37(6):465-469.

(125) Kliner M, Keenan A, Sinclair D, Ghebrehewet S, Garner P. Influenza vaccination for healthcare workers in the UK: appraisal of systematic reviews and policy options. BMJ Open 2016;6(9):e012149.

(126) Kostova D, Reed C, Finelli L, Cheng PY, Gargiullo PM, Shay DK, et al. Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011. PLoS One 2013;8(6):e66312.

(127) Krubiner C.B., Faden R.R., Karron R.A., Little M.O., Lysterly A.D., Abramson J.S., et al. Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response. Vaccine 2019(pagination):ate of Pubaton: 2019.

(128) Kuchar E., Ludwikowska K., Szenborn L., Antczak A., Mastalerz-Migas A., Nitsch-Osuch A. Knowledge regarding influenza and influenza vaccination in general population: Results of a national survey in Poland. Adv Exp Med Biol 2018;1108:55-61.

(129) Kuster S.P., Shah P.S., Coleman B.L., Lam P.P., Tong A., Wormsbecker A., et al. Incidence of influenza in healthy adults and healthcare workers: A systematic review and meta-analysis. PLoS ONE 2011;6(10) (pagination):Arte Number: e26239. ate of Pubaton: 18 Ot 2011.

(130) LMST Lægemiddelstyrelsen. . Godkendelse og kontrol - godkendelse af medicin. . Senest hentet: 6.okt.2020. Link: <https://laegemiddelstyrelsen.dk/da/godkendelse/godkendelse-af-medicin/>.

(131) Lambert M. Influenza Vaccination Recommendations for 2017-2018: Updates from ACIP. Am Fam Physician 2017;96(8):545-546.

(132) Le Saux N, Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Guidelines for the management of suspected and confirmed bacterial meningitis in Canadian children older than one month of age. Paediatr child health 2014;19(3):141-52.

(133) Lee J.K.H., Lam G.K.L., Shin T., Kim J., Krishnan A., Greenberg D.P., et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Review of Vaccines 2018;17(5):435-443.

(134) Lemaitre M, Meret T, Rothan-Tondeur M, Belmin J, Lejonc JL, Luquel L, et al. Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial. J Am Geriatr Soc 2009;57(9):1580-1586.



- (135) Levin Y., Kochba E., Shukarev G., Rusch S., HerreraTaracena G., van Damme P. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. *Vaccine* 2016;34(44):5262-5272.
- (136) Li R, Fang H, Li Y, Liu Y, Pellegrini M, Podda A. Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects. *Immun Ageing* 2008;5:2-4933-5-2.
- (137) Lietz J., Westermann C., Nienhaus A., Schablon A. The occupational risk of influenza A (H1N1) infection among healthcare personnel during the 2009 pandemic: A systematic review and meta-analysis of observational studies. *PLoS ONE* 2016;11(8) (pagination):Arte Number: e0162061. ate of Pubaton: August 2016.
- (138) LiKimMoy J., Yin J.K., Rashid H., Khandaker G., King C., Wood N., et al. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children. *Eurosurveillance* 2015;20(24) (pagination):Arte Number: 21159. ate of Pubaton: 18 Jun 2015.
- (139) Li-Kim-Moy J,P., Yin JK, Heron L, Leask J, Lambert SB, Nissen M, et al. Influenza vaccine efficacy in young children attending childcare: A randomised controlled trial. *J Paediatr Child Health* 2017;53(1):47-54.
- (140) Liu W., Ma X., Zhou W. Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis. *Medicine* 2019;98(22):e15868.
- (141) Longini IM, Halloran ME, Nizam A, Wolff M, Mendelman PM, Fast PE, et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. *Vaccine* 2000;18(18):1902-1909.
- (142) Lu Y, Chillarige Y, Izurieta HS, Wei Y, Xu W, Lu M, et al. Effect of Age on Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries Aged ≥65 Years. *J Infect Dis* 2019;220(9):1511-1520.
- (143) Luksic I, Clay S, Falconer R, Pulanic D, Rudan I, Campbell H, et al. Effectiveness of seasonal influenza vaccines in children -- a systematic review and meta-analysis. *Croat Med J* 2013;54(2):135-145.
- (144) Maeda T, Shintani Y, Miyamoto H, Kawagoe H, Nakano K, Nishiyama A, et al. Prophylactic effect of inactivated influenza vaccine on young children. *Pediatr Int* 2002;44(1):43-46.
- (145) Maeda T, Shintani Y, Nakano K, Terashima K, Yamada Y. Failure of inactivated influenza A vaccine to protect healthy children aged 6-24 months. *Pediatr Int* 2004;46(2):122-125.
- (146) Maglione M.A., Das L., Raaen L., Smith A., Chari R., Newberry S., et al. Safety of vaccines used for routine immunization of US children: A systematic review. *Pediatrics* 2014;134(2):325-337.
- (147) Maldonado Y.A., Zaoutis T.E., Banerjee R., Barnett E.D., Campbell J.D., Gerber J.S., et al. Recommendations for prevention and control of influenza in children, 2018-2019. *Pediatrics* 2018;142(4) (pagination):Arte Number: e20182367. ate of Pubaton: October 2018.
- (148) Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. *Am J Epidemiol* 2012;176(6):527-533.



SUNDHEDSSTYRELSEN

- (149) Manuel O., Estabrook M. RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019:e13511.
- (150) Manzoli L., Ioannidis J.P.A., Flacco M.E., De Vito C., Villari P. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: A critical review and re-analysis of 15 meta-analyses. Human Vaccines and Immunotherapeutics 2012;8(7):851-862.
- (151) McBride DL. Updated Guidelines on Infection Prevention in Pediatric Ambulatory Settings. J Pediatr Nurs 2018.
- (152) McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013;13(6):485-496.
- (153) McGuire A, Drummond M, Keeping S. Childhood and adolescent influenza vaccination in Europe: A review of current policies and recommendations for the future. Expert Rev Vaccines 2016;15(5):659-70.
- (154) Sanofi Pasteur Medical Information. . Trivalent Influenza Vaccine (Split Virion, Inactivated) High Dose, suspension for injection in pre-filled syringe (Sanofi Pasteur). . Senest hentet: 29.sept.2020. Link: <https://www.medicines.org.uk/emc/product/10012/smpc>.
- (155) Mendez-Figueroa H, Raker C, Anderson BL. Neonatal characteristics and outcomes of pregnancies complicated by influenza infection during the 2009 pandemic. Am J Obstet Gynecol 2011;204(6 Suppl 1):S58-63.
- (156) Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013;347:f5061.
- (157) Michiels B, Philips H, Coenen S, Yane F, Steinhäuser T, Stuyck S, et al. The effect of giving influenza vaccination to general practitioners: a controlled trial [NCT00221676. BMC Med 2006;4:17-7015-4-17.
- (158) Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999;17(2):99-104.
- (159) Mølgaard-Nielsen D, Fischer TK, Krause TG, Hviid A. Effectiveness of maternal immunization with trivalent inactivated influenza vaccine in pregnant women and their infants. J Intern Med 2019;286(4):469-480.
- (160) Moore DL. Vaccine recommendations for children and youth for the 2018/2019 influenza season. Paediatr child health 2018;23(8):565-566.
- (161) Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008;5(3):e74.
- (162) Nace DA, Lin CJ, Ross TM, Saracco S, Churilla RM, Zimmerman RK. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. J Infect Dis 2015;211(12):1915-1924.



SUNDHEDSSTYRELSEN

(163) Nasjonalt kunnskapssenter for helsetjenesten, Norge. Effekter av tiltak mot sykefravær og uførhet hos helsepersonell. Rapport fra Kunnskapssenteret nr 2-2014 Systematisk oversikt Kunnskapssenter, 2014. 74 s. (Nr.2-2014).

(164) National Advisory Committee on Immunization (NACI). . National Advisory Committee on Immunization (NACI), Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020-2021 Opdateret: 2020. Senest hentet: 05/19.2020. Link: <https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2020-2021.html>.

(165) National Institute for Health and Welfare, Finland. . Influenza vaccination coverage. . Senest hentet: 6.okt 2020. Link: <https://www.thl.fi/roko/rokotusrekisteri/atlas/atlas-en.html?show=influenza>.

(166) Neuzil KM, Mellen BG, Wright PF, Mitchel EF,Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342(4):225-231.

(167) Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998;148(11):1094-1102.

(168) Ng ANM, Lai CKY. Effectiveness of seasonal influenza vaccination in healthcare workers: a systematic review. J Hosp Infect 2011;79(4):279-286.

(169) Nichols MK, Andrew MK, Hatchette TF, Ambrose A, Boivin G, Bowie W, et al. Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). Vaccine 2018;36(16):2166-2175.

(170) Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003;362(9397):1733-1745.

(171) Nielsen J, Krause TG, Mølbak K. Influenza-associated mortality determined from all-cause mortality, Denmark 2010/11-2016/17: The FluMOMO model. Influenza Other Respir Viruses 2018;12(5):591-604.

(172) Nielsen J, Mazick A, Glismann S, Mølbak K. Excess mortality related to seasonal influenza and extreme temperatures in Denmark, 1994-2010. BMC Infect Dis 2011;11:350-2334-11-350.

(173) Nielsen J, Vestergaard LS, Richter L, Schmid D, Bustos N, Asikainen T, et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered? Clin Microbiol Infect 2019;25(10):1266-1276.

(174) Nohynek H, Baum U, Syrjanen R, Ikonen N, Sundman J, Jokinen J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill 2016;21(38):10.2807/1560-7917.ES.2016.21.38.30346.

(175) Nohynek H, Baum U, Syrjänen R, Ikonen N, Sundman J, Jokinen J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill 2016;21(38):30346. doi: 10.2807/1560-7917.ES.2016.21.38.30346.

(176) Norhayati MN, Ho JJ, Azman MY. Influenza vaccines for preventing acute otitis media in infants and children. Cochrane Database of Systematic Reviews 2017;10:010089.



- (177) Nunes MC, Aqil AR, Omer SB, Madhi SA. The Effects of Influenza Vaccination during Pregnancy on Birth Outcomes: A Systematic Review and Meta-Analysis. *Am J Perinatol* 2016;33(11):1104-1114.
- (178) Ohmit SE, Petrie JG, Malosh RE, Johnson E, Truscon R, Aaron B, et al. Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013-2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated. *J Infect Dis* 2016;213(8):1229-1236.
- (179) Osterholm M.T., Kelley N.S., Sommer A., Belongia EA. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. *The Lancet Infectious Diseases* 2012;12(1):36-44.
- (180) Osterhus SF. Influenza vaccination: a summary of Cochrane Reviews. *European Journal of Clinical Microbiology and Infectious Diseases* 2014;34(2):205-213.
- (181) Pebody R, Djennad A, Ellis J, Andrews N, Marques DFP, Cottrell S, et al. End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18. *Euro Surveill* 2019;24(31):1800488. doi: 10.2807/1560.
- (182) Pebody R, McMenamin J, Nohynek H. Live attenuated influenza vaccine (LAIV): recent effectiveness results from the USA and implications for LAIV programmes elsewhere. *Arch Dis Child* 2018;103(1):101-105.
- (183) Pebody R, Warburton F, Andrews N, Ellis J, von Wissmann B, Robertson C, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. *Euro Surveill* 2015;20(36):10.2807/1560-7917.ES.2015.20.36.30013.
- (184) Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. *Euro Surveill* 2016;21(38):10.2807/1560-7917.ES.2016.21.38.30348.
- (185) Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17. *Euro Surveill* 2017;22(44):17-00306. doi: 10.2807/1560-7917.ES.2017.22.44.17-00306.
- (186) Pebody RG, Green HK, Andrews N, Boddington NL, Zhao H, Yonova I, et al. Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. *Euro Surveill* 2015;20(39):10.2807/1560-7917.ES.2015.20.39.30029.
- (187) Pebody RG, McLean E, Zhao H, Cleary P, Bracebridge S, Foster K, et al. Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. *Euro Surveill* 2010;15(20):19571.
- (188) Pebody RG, Whitaker H, Ellis J, Andrews N, Marques DFP, Cottrell S, et al. End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19. *Vaccine* 2020;38(3):489-497.
- (189) Pebody RG, Zhao H, Whitaker HJ, Ellis J, Donati M, Zambon M, et al. Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018/19, England. *Vaccine* 2020;38(2):158-164.
- (190) Pellerin-Leblanc A.-A., Derynck M., Dow K. Improving communication in the NICU: Parental perceptions and knowledge about resident physicians. *Paediatr Child Health* 2018;23:e47-e48.



- (191) Piedra PA, Gaglani MJ, Kozinetz CA, Herschler G, Riggs M, Griffith M, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. *Vaccine* 2005;23(13):1540-1548.
- (192) Piedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J, et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. *Pediatrics* 2002;110(4):662-672.
- (193) Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M, UKOSS. Perinatal outcomes after maternal 2009/H1N1 infection: national cohort study. *BMJ* 2011;342:d3214.
- (194) Pillsbury AJ, Fathima P, Quinn HE, Cashman P, Blyth CC, Leeb A, et al. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older. *JAMA Netw Open* 2020;3(5):e204079.
- (195) Ploin D, Liberas S, Thouvenot D, Fouilhoux A, Gillet Y, Denis A, et al. Influenza burden in children newborn to eleven months of age in a pediatric emergency department during the peak of an influenza epidemic. *Pediatr Infect Dis J* 2003;22(10 Suppl):S218-22.
- (196) Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, et al. The underrecognized burden of influenza in young children. *N Engl J Med* 2006;355(1):31-40.
- (197) Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2006;(1):CD002733. doi(1):CD002733.
- (198) Potter J, Stott DJ, Roberts MA, Elder AG, O'Donnell B, Knight PV, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. *J Infect Dis* 1997;175(1):1-6.
- (199) Public Health Agency of Canada. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2017–2018 Public Health Agency of Canada, May 2017. 76 s.
- (200) Puig-Barbera J, Diez-Domingo J, Arnedo-Pena A, Ruiz-Garcia M, Perez-Vilar S, Mico-Esparza JL, et al. Effectiveness of the 2010-2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study. *Vaccine* 2012;30(39):5714-5720.
- (201) Puig-Barbera J, Diez-Domingo J, Perez Hoyos S, Belenguer Varea A, Gonzalez Vidal D. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. *Vaccine* 2004;23(3):283-289.
- (202) Puig-Barbera J, Diez-Domingo J, Varea AB, Chavarri GS, Rodrigo JA, Hoyos SP, et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. *Vaccine* 2007;25(42):7313-7321.
- (203) Puig-Barbera J, Natividad-Sancho A, Calabuig-Perez J, Lluch-Rodrigo JA, Pastor-Villalba E, Martinez-Ubeda S, et al. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. *Vaccine* 2013;31(37):3995-4002.
- (204) Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. *N Engl J Med* 2001;344(12):889-896.



- (205) Richardson DM, Medvedeva EL, Roberts CB, Linkin DR, Centers for Disease Control and Prevention Epicenter Program. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. *Clin Infect Dis* 2015;61(2):171-176.
- (206) Riphagen-Dalhuisen J, Burgerhof JG, Frijstein G, van der Geest-Blankert AD, Danhof-Pont MB, de Jager HJ, et al. Hospital-based cluster randomised controlled trial to assess effects of a multi-faceted programme on influenza vaccine coverage among hospital healthcare workers and nosocomial influenza in the Netherlands, 2009 to 2011. *Euro Surveill* 2013;18(26):20512.
- (207) Robinson CL, Bernstein H, Romero JR, Szilagyi P. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger -- United States, 2019. *MMWR SURVEILLANCE SUMM* 2019;68(5):112-114.
- (208) Rolfes MA, Goswami D, Sharmeen AT, Yeasmin S, Parvin N, Nahar K, et al. Efficacy of trivalent influenza vaccine against laboratory-confirmed influenza among young children in a randomized trial in Bangladesh. *Vaccine* 2017;35(50):6967-6976.
- (209) Rondy M, El Omeiri N, Thompson MG, Levêque A, Moren A, Sullivan SG. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. *J Infect* 2017;75(5):381-394.
- (210) Rudenko LG, Lonskaya NI, Klimov AI, Vasilieva RI, Ramirez A. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds. *Bull World Health Organ* 1996;74(1):77-84.
- (211) Rudenko LG, Slepishkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. *J Infect Dis* 1993;168(4):881-887.
- (212) Ruf BR, Colberg K, Frick M, Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. *Infection* 2004;32(4):191-198.
- (213) Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T. Cost-effectiveness of influenza vaccination of healthy children. *Vaccine* 2006;24(23):4934-4941.
- (214) Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. *Pediatr Infect Dis J* 1999;18(9):779-783.
- (215) Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B, et al. Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison. *Hum Vaccin Immunother* 2013;9(11):2460-2473.
- (216) Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly. *Clin Vaccine Immunol* 2014;21(7):989-996.
- (217) Shang M, Blanton L, Brammer L, Olsen SJ, Fry AM. Influenza-Associated Pediatric Deaths in the United States, 2010-2016. *Pediatrics* 2018;141(4):e20172918. doi: 10.1542/peds.2017-2918. Epub 2018 Feb 12.
- (218) Shay DK, Chillarige Y, Kelman J, Forshee RA, Foppa IM, Werneck M, et al. Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries



SUNDHEDSSTYRELSEN

in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014. J Infect Dis 2017;215(4):510-517.

(219) Shields GE, Elvidge J, Davies LM. A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union. BMJ Open 2017;7(6):e014847-2016-014847.

(220) Spadea A, Unim B, Colamesta V, Meneghini A, D'Amici AM, Giudiceandrea B, et al. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study. Vaccine 2014;32(41):5290-5294.

(221) Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003;21(11-12):1268-1274.

(222) Statens Serum institut SSI. . Invasiv pneumokoksygdom - opgørelse over sygdomsforekomst 2017
Senest redigeret den 11. oktober 2018. Opdateret: Senest redigeret den 11. oktober 2018. Senest hentet: 8.okt.2020. Link: <https://www.ssi.dk/sygdomme-beredskab-og-forskning/sygdomsovervaagning/i/invasiv-pneumokoksygdom---opgoerelse-over-sygdomsforekomst-2017>.

(223) Statens Serums Institut SSI. . Influenzavaccination. Opdateret: Senest redigeret den 10. oktober 2019.010920. Link: <https://www.ssi.dk/vaccinationer/influenzavaccination>.

(224) Sundhedsstyrelsen SST. . Børnevaccinationsprogrammet (pjece). Opdateret: PJECER 14 MAR 2019. Senest hentet: 8.okt.2020. Link: <https://www.sst.dk/da/udgivelser/2019/boernevaccinationsprogrammet-pjece>.

(225) SST S. Børnevaccinationsprogrammet 2018 Årsrapport 2018 Sundhedsstyrelsen, 2019. 98 s. (version 1, 23.04.2019).

(226) SST S. Etik i forebyggelse og sundhedsfremme Sundhedsstyrelsen, 2009. 59 s.

(227) Staat MA, Griffin MR, Donauer S, Edwards KM, Szilagyi PG, Weinberg GA, et al. Vaccine effectiveness for laboratory-confirmed influenza in children 6-59 months of age, 2005-2007. Vaccine 2011;29(48):9005-9011.

(228) Norge Statens Legemiddelverk. . Guidelines for the submission of documentation for single technology assessment (STA) of pharmaceuticals. Opdateret: May 20th 2020. Senest hentet: 9.okt.2020. Link: <https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/guidelines-for-the-submission-of-documentation-for-single-technology-assessment-sta-of-pharmaceuticals>.

(229) Statens Serum institut. . Influenzasæsonen - opgørelse over sygdomsforekomst 2018/19 . Opdateret: Senest redigeret den 5. juni 2019. Senest hentet: 010920. Link: <https://www.ssi.dk/sygdomme-beredskab-og-forskning/sygdomsovervaagning/i/influenzasaesonen---opgoerelse-over-sygdomsforekomst-2018-19>.

(230) SSI Statens Serum institut. . Influenzasæsonen - opgørelse over sygdomsforekomst 2019/20 Senest redigeret den 24. juni 2020. Opdateret: Senest redigeret den 24. juni 2020. Senest hentet: 8.okt.2020. Link: <https://www.ssi.dk/sygdomme-beredskab-og-forskning/sygdomsovervaagning/i/influenzasaesonen---opgoerelse-over-sygdomsforekomst-2019-20>.



SUNDHEDSSTYRELSEN

- (231) SSI Statens Serum Institut. . Overvågning af vaccinationer
. Opdateret: Senest redigeret den 22. december 2017. Senest hentet: 9.okt 2020. Link:
<https://www.ssi.dk/sygdomme-beredskab-og-forskning/sygdomsovervaagning/v/vaccinationsovervaagning>.
- (232) SSI Statens Serum Institut. . Andel vaccineret med Sæsoninfluenza-vaccination (aldersgruppe), Sæson: 2009/2010-2019/2020. Opdateret: 2020. Senest hentet: 11/09.2020. Link:
<https://statistik.ssi.dk/sygdomsdata#!/?vaccination=14&sex=3&agegroup=10&landsdel=100&xaxis=Season&yaxis=Vaccination&show=Table&datatype=Vaccination>.
- (233) Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.
- (234) Sundheds- og Ældreministeriet. . Bekendtgørelse om adgang til og registrering m.v. af lægemiddel- og vaccinationsoplysninger. . Senest hentet: 8.okt.2020. Link:
<https://www.retsinformation.dk/eli/lt/2018/1615>.
- (235) Sundhedsstyrelsen. METODEHÅNDBOGEN Model for udarbejdelse af nationale kliniske retningslinjer. version 3. Sundhedsstyrelsen, 2018. 57 s.
- (236) SST Sundhedsstyrelsen. . Tilbud om vaccination til risikogrupper. Opdateret: Opdateret 15 JUL 2019. Senest hentet: 010920. Link:
<https://www.sst.dk/da/Viden/Vaccination/Inflenzavaccination/Tilbud-om-vaccination-til-risikogrupper>.
- (237) SST Sundhedsstyrelsen. . Vaccination - influenzavaccination - kronisksyge. . Senest hentet: 29.sep.2020. Link: <https://www.sst.dk/da/Viden/Vaccination/Inflenzavaccination/Kronisk-syge>.
- (238) Taksler G.B., Pfoh E.R., Stange K.C., Rothberg MB. Association Between Number of Preventive Care Guidelines and Preventive Care Utilization by Patients. Am J Prev Med 2018;55(1):1-10.
- (239) Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007;26(7):619-628.
- (240) Tamma PD, Ault KA, del Rio C, Steinhoff MC, Halsey NA, Omer SB. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2009;201(6):547-552.
- (241) Tandvårds- och Läkemedelsförmansverket. . Introduktion till hälsoekonomisk utvärdering. Opdateret: Senast uppdaterad 12 maj 2020. Senest hentet: 9.okt.2020. Link:
<https://www.tlv.se/lakemedel/halsoekonomi.html>.
- (242) the Government Digital Service, UK. . Influenza: the green book, chapter 19 Influenza immunisation information including updates for public health professionals. 27 pages. Opdateret: Last updated 23 April 2019. Published 20 March 2013. Link:
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/796886/GreenBook_Chapter_19_Influenza_April_2019.pdf.
- (243) The GRADE working group. . GRADE. . Senest hentet: 29.sep.2020. Link:
<https://gradeworkinggroup.org/>.
- (244) Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions. Cochrane Database of Systematic Reviews 2016;(6)-2016 Jun 02.



- (245) Toback SL, Ambrose CS, Eaton A, Hansen J, Aukes L, Lewis N, et al. A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age. *Vaccine* 2013;31(14):1812-1818.
- (246) Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, et al. Immunogenicity and safety of Fluzone((R)) intradermal and high-dose influenza vaccines in older adults ≥ 65 years of age: a randomized, controlled, phase II trial. *Vaccine* 2014;32(21):2507-2517.
- (247) Van Buynder PG, Konrad S, Kersteins F, Preston E, Brown PD, Keen D, et al. Healthcare worker influenza immunization vaccinate or mask policy: strategies for cost effective implementation and subsequent reductions in staff absenteeism due to illness. *Vaccine* 2015;33(13):1625-1628.
- (248) Van Buynder PG, Konrad S, Van Buynder JL, Brodtkin E, Krajden M, Ramler G, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. *Vaccine* 2013;31(51):6122-6128.
- (249) van Hoek AJ, Underwood A, Jit M, Miller E, Edmunds WJ. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. *PLoS One* 2011;6(3):e17030.
- (250) van Leeuwen E, Klepac P, Thorrington D, Pebody R, Baguelin M. fluEvidenceSynthesis: An R package for evidence synthesis based analysis of epidemiological outbreaks. *PLoS Comput Biol* 2017;13(11):e1005838.
- (251) Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. *Pediatrics* 2006;118(6):2298-2312.
- (252) Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. *N Engl J Med* 2011;365(15):1406-1416.
- (253) Vestergaard LS, Nielsen J, Krause TG, Espenhain L, Tersago K, Bustos Sierra N, et al. Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017. *Euro Surveill* 2017;22(14):30506. doi: 10.2807/1560-7917.ES.2017.22.14.30506.
- (254) Weingarten S, Staniloff H, Ault M, Miles P, Bamberger M, Meyer RD. Do hospital employees benefit from the influenza vaccine? A placebo-controlled clinical trial. *J Gen Intern Med* 1988;3(1):32-37.
- (255) Wendelboe AM, Avery C, Andrade B, Baumbach J, Landen MG. Importance of employee vaccination against influenza in preventing cases in long-term care facilities. *Infect Control Hosp Epidemiol* 2011;32(10):990-997.
- (256) WHO WHO.
Recommended composition of influenza virus vaccines for use in the 2020-2021 northern hemisphere influenza season 2020.
- (257) World Health Organisation WHO. . Global influenza strategy 2019-2030. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. Opdateret: 2019. Senest hentet: 19/2-2020. Link: <https://apps.who.int/iris/handle/10665/311184>.
- (258) WHO WHO. Vaccines against influenza WHO position paper - November 2012. *Wkly Epidemiol Rec* 2012;87(47):461-76.



SUNDHEDSSTYRELSEN

- (259) World Health Organisation WHO. . National influenza vaccination policies for children. Opdateret: 13.03.2019. Senest hentet: 11.09.2020. Link: https://gateway.euro.who.int/en/indicators/infl_5-influenza-vaccination-recommendation-children/visualizations/#id=31647.
- (260) World Health Organisation WHO. . National influenza vaccination policies for health care workers. Opdateret: 13.03.2019. Senest hentet: 11.09.2020. Link: https://gateway.euro.who.int/en/indicators/infl_3-influenza-vaccination-recommendation-health-care-workers/.
- (261) World Health Organisation WHO. . Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season, 21 February 2019. Opdateret: (updated on 21 March 2019). Senest hentet: 23.03.2020. Link: https://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/.
- (262) World Health Organisation WHO. . Influenza - Vaccines - WHO recommendations on the composition of influenza virus vaccines . . Senest hentet: 1.sept.2020. Link: <https://www.who.int/influenza/vaccines/virus/recommendations/en/>.
- (263) Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999;281(10):908-913.
- (264) Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Setta AM, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine 2017;35(21):2775-2780.
- (265) WHO World Health Organization. . Vaccination. . Senest hentet: 29.sep.2020. Link: <https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/vaccination>.
- (266) Yin JK, Heywood AE, Georgousakis M, King C, Chiu C, Isaacs D, et al. Systematic Review and Meta-analysis of Indirect Protection Afforded by Vaccinating Children Against Seasonal Influenza: Implications for Policy. Clin Infect Dis 2017;65(5):719-728.
- (267) Yin JK, Lahra MM, Iskander M, Lambert SB, Heron L, Nissen MD, et al. Pilot study of influenza vaccine effectiveness in urban Australian children attending childcare. J Paediatr Child Health 2011;47(12):857-862.
- (268) Young-Xu Y, Snider JT, van Aalst R, Mahmud SM, Thommes EW, Lee JKH, et al. Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method. Vaccine 2019;37(11):1484-1490.
- (269) Young-Xu Y, Van Aalst R, Mahmud SM, Rothman KJ, Snider JT, Westreich D, et al. Relative Vaccine Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among Veterans Health Administration Patients. J Infect Dis 2018;217(11):1718-1727.
- (270) Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012;54(10):1427-1436.